Holen Sie sich die Stockscreener-App
39.68
0.79%
0.31
Schlusskurs vom Vortag:
$39.37
Offen:
$38.96
24-Stunden-Volumen:
414.53K
Relative Volume:
0.40
Marktkapitalisierung:
$3.12B
Einnahmen:
$866.00K
Nettoeinkommen (Verlust:
$-283.65M
KGV:
-9.2993
EPS:
-4.267
Netto-Cashflow:
$-226.25M
1W Leistung:
+1.43%
1M Leistung:
+1.61%
6M Leistung:
+34.33%
1J Leistung:
+74.19%
1-Tages-Spanne:
$38.90
$39.81
1-Wochen-Bereich:
$38.74
$40.55
52-Wochen-Spanne:
$22.10
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
39.68 | 3.14B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Hochstufung | Barclays | Underweight → Overweight |
| 2026-03-23 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Underweight |
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside - TradingView
Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock - MarketBeat
CLDX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Celldex Reports Second Quarter Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million - Bitget
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex: Q2 Earnings Snapshot - Barchart.com
Celldex Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M - marketscreener.com
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary - TradingView
Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M - Stock Titan
Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celldex reports Q2 net loss of $73.5M; cash and marketable securities $717.6M at June 30, 2026 - TradingView
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week HighTime to Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com - Investing.com South Africa
Celldex Therapeutics stock hits 52-week high at $40.30 - Investing.com
Celldex Therapeutics earnings up next as Phase III data looms - Investing.com
Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsight - The Manila Times
CLDX Q2'26 Earnings: EPS estimate is (1.06) USD - TradingView
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Biotechnology Innovator with 51% Potential Upside - DirectorsTalk Interviews
Celldex Therapeutics, Inc. $CLDX Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Celldex Therapeutics (CLDX) Eases 1.1% as Shares Test Middle of Trading RangeTriple EMA - vinanet.vn
CLDX Q2'26 Earnings: revenue estimate is 734.92K USD - TradingView
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - MarketBeat
Eversept Partners LP Has $56.72 Million Stock Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380 - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celldex Therapeutics Inc-Aktie (CLDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):